EB-1020 (Centanafadine) high dose for attention deficit disorder with hyperactivity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 28 Jul 2025: Trial registered, NCT07087327
  2. 16 Sep 2025: Trial started, NCT07087327

The trials

NCT07087327: A Long-term Trial of EB-1020 in Pediatric Patients With ADHD

State
Under way
Phase
Phase 3
People
180 planned
Started
16 Sep 2025
Primary completion
Aug 2027
Arms
EB-1020 (QD XR Capsules) high dose
Results
None posted
  1. 28 Jul 2025: Trial registered
  2. 16 Sep 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.